Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.
Also called NCT01293669
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 440 participants
- Sponsor
- Targacept Inc.
- Registry
-
NCT01293669
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01293669. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- TC-6987
- Intervention (Drug)
- Placebo
- Lead sponsor
- Targacept Inc.
Record details
- Record id
cardio:ct-nct01293669- Content hash
2b872a10a9231e97097e391a6fb62037a58e1d71c7f54883c31a8c4079c29779